Table 4.
Excess lengths of stay and costs associated with AKI by the KDIGO definition according to quantile regression analyses
| Percentile | All AKI Stages | Stage 1 | Stage 2 | Stage 3 |
|---|---|---|---|---|
| Length of stay, d | ||||
| 10th | 1.5 (1.4–1.6) | 1.3 (1.2–1.5) | 2.0 (1.7–2.3) | 2.0 (1.5–2.5) |
| 50th | 2.8 (2.6–2.9) | 2.5 (2.3–2.7) | 4.2 (3.5–4.9) | 6.4 (5.3–7.5) |
| 90th | 6.2 (5.4–7.0) | 4.7 (4.1–5.4) | 10.5 (8.6–12.4) | 17.6 (14.3–21.0) |
| Costs, $1000 USD | ||||
| 10th | 3.5 (3.1–3.8) | 3.1 (2.8–3.5) | 4.2 (3.2–5.3) | 5.2 (3.8–6.5) |
| 50th | 7.1 (6.4–7.8) | 5.4 (4.7–6.1) | 15.2 (13.3–17.2) | 27.3 (22.6–32.0) |
| 90th | 18.7 (16.4–21.0) | 13.1 (10.9–15.4) | 35.4 (26.0–44.9) | 88.8 (72.6–105.0) |
Results are presented as the increase in length of stay and costs in patients with AKI versus without AKI according to the KDIGO definition, using multivariable adjusted quantile regression models adjusting for age, sex, race, procedures, diagnoses, laboratory values including estimated GFR, and diagnosis-related group weights. Values represent the increase in days or $1000 USD in those with AKI versus without AKI. KDIGO, Kidney Disease Improving Global Outcomes.